What's Happening?
A study conducted by scientists at the University of California, Los Angeles (UCLA) suggests that creatine, a supplement commonly used to improve athletic performance, may also enhance the body's immune response against cancer. The research, published
in the journal iScience, found that creatine boosts the activity of dendritic cells, which play a crucial role in directing killer T-cells to attack cancer cells. In mouse models of melanoma, daily injections of creatine slowed tumor growth and increased dendritic cell activity, attracting more immune cells to the tumor site. While the study's findings are promising, they are based on research conducted in mice and cells, not human patients.
Why It's Important?
The study highlights creatine's potential as a cost-effective supplement to support cancer immunotherapy, which currently benefits only a subset of patients. By energizing dendritic cells, creatine could enhance the immune system's ability to fight cancer, potentially improving the effectiveness of existing immunotherapies. This discovery could lead to new strategies for cancer treatment, offering hope to patients who do not respond to current therapies. However, further research is needed to determine the supplement's efficacy and safety in humans before any medical recommendations can be made.
What's Next?
Researchers will likely conduct clinical trials to test creatine's effectiveness in human cancer patients and explore its potential as a supplement to enhance immunotherapy. The study's authors suggest that creatine could be used to improve the quality of dendritic cell-based vaccines and support the immune response in patients undergoing cancer treatment. As the research progresses, scientists will aim to understand the mechanisms by which creatine influences immune cells and its potential applications in cancer therapy.
